Payment overview · 2025
General Payments
$464.40
16 reported records · 9 companies
Healthcare provider profile · identity verified
Mohammed Imran Iqbal, MD
Allopathic & Osteopathic Physicians|Internal Medicine · WEST HILLS, CA · NPI 1578574596
Verified facts
What the public records show
CMS Open Payments records show Mohammed Imran Iqbal, MD received $464.40 in general payments during 2025 across 16 reported records.
Amgen Inc. accounted for 37.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 110 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Wegovy as an associated drug or biological on 183056 records involving 75256 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Wegovy by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $175.05 | 37.7% | 7 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$136.48 | 29.4% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $30.86 | 6.7% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $24.76 | 5.3% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $23.97 | 5.2% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $23.37 | 5.0% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $22.02 | 4.7% | 1 | 2025 |
| Almatica Pharma LLC | Unresolved — no canonical attribution shown | $14.16 | 3.0% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $13.73 | 3.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $464.40 | 16 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $158.94 | 6 | 2025 |
Source payment records
|
|||||
| COREVALVE EVOLUT R Normalized: corevalve evolut r |
Device | Medtronic, Inc. | $114.35 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $107.04 | 4 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $30.86 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $30.86 | 1 | 2025 |
Source payment records
|
|||||
| RECORLEV Normalized: recorlev |
Drug | Xeris Pharmaceuticals, Inc. | $24.76 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $23.97 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $23.37 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $23.37 | 1 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $22.13 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $22.02 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $16.11 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $16.11 | 1 | 2025 |
Source payment records
|
|||||
| LOREEV XR Normalized: loreev xr |
Drug | Almatica Pharma LLC | $14.16 | 1 | 2025 |
Source payment records
|
|||||
| TERIPARATIDE Normalized: teriparatide |
Drug | Almatica Pharma LLC | $14.16 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $13.73 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $13.73 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 64 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 110 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
54 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
64 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
110 | 26 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Wegovy open payments reported associated product |
CMS Open Payments — General Payments 183056 supporting records · 75256 recipient NPIs · example record 1188130070 |
Wegovy · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 717 | 210 |
| Amlodipine Besylate | Amlodipine Besylate | 250 | 76 |
| Levothyroxine Sodium | Levothyroxine Sodium | 233 | 66 |
| Metformin Hcl | Metformin Hcl | 222 | 71 |
| Omeprazole | Omeprazole | 222 | 72 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 211 | 72 |
| Zolpidem Tartrate | Zolpidem Tartrate | 197 | 35 |
| Lisinopril | Lisinopril | 179 | 58 |
| Pantoprazole Sodium | Pantoprazole Sodium | 141 | 33 |
| Alprazolam | Alprazolam | 140 | 39 |
| Losartan Potassium | Losartan Potassium | 137 | 41 |
| Metoprolol Succinate | Metoprolol Succinate | 135 | 39 |
| Trazodone Hcl | Trazodone Hcl | 128 | 36 |
| Escitalopram Oxalate | Escitalopram Oxalate | 126 | 35 |
| Montelukast Sodium | Montelukast Sodium | 119 | 38 |
| Hydrochlorothiazide | Hydrochlorothiazide | 115 | 32 |
| Ozempic | Semaglutide | 110 | 26 |
| Tamsulosin Hcl | Tamsulosin Hcl | 100 | 35 |
| Fluticasone Propionate | Fluticasone Propionate | 86 | 32 |
| Meloxicam | Meloxicam | 76 | 34 |
| Furosemide | Furosemide | 75 | 20 |
| Simvastatin | Simvastatin | 72 | 23 |
| Alendronate Sodium | Alendronate Sodium | 71 | 23 |
| Gabapentin | Gabapentin | 71 | 23 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 69 | 28 |
| Famotidine | Famotidine | 65 | 24 |
| Mounjaro | Tirzepatide | 64 | 12 |
| Bupropion Xl | Bupropion Hcl | 59 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 56 | 19 |
| Jardiance | Empagliflozin | 54 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 53 | 21 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 51 | 23 |
| Ibuprofen | Ibuprofen | 50 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 49 | 15 |
| Metoprolol Tartrate | Metoprolol Tartrate | 49 | 13 |
| Eliquis | Apixaban | 47 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 47 | 13 |
| Benazepril Hcl | Benazepril Hcl | 46 | 12 |
| Chlorthalidone | Chlorthalidone | 45 | 12 |
| Azelastine Hcl | Azelastine Hcl | 44 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 43 | 12 |
| Potassium Chloride | Potassium Chloride | 42 | 14 |
| Allopurinol | Allopurinol | 41 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 39 | 13 |
| Spironolactone | Spironolactone | 37 | 12 |
| Carvedilol | Carvedilol | 36 | 12 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 36 | suppressed |
| Lansoprazole | Lansoprazole | 36 | suppressed |
| Ondansetron Odt | Ondansetron | 36 | 14 |
| Synthroid | Levothyroxine Sodium | 36 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 35 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 34 | suppressed |
| Methylprednisolone | Methylprednisolone | 33 | 23 |
| Atenolol | Atenolol | 32 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 32 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 32 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 31 | 12 |
| Doxazosin Mesylate | Doxazosin Mesylate | 30 | suppressed |
| Januvia | Sitagliptin Phosphate | 30 | suppressed |
| Prednisone | Prednisone | 29 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 29 | 11 |
| Valacyclovir | Valacyclovir Hcl | 29 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 28 | suppressed |
| Temazepam | Temazepam | 28 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 27 | suppressed |
| Diphenhydramine Hcl | Diphenhydramine Hcl | 25 | suppressed |
| Fenofibrate | Fenofibrate | 25 | suppressed |
| Xarelto | Rivaroxaban | 25 | suppressed |
| Famotidine | Famotidine/Pf | 24 | suppressed |
| Glimepiride | Glimepiride | 24 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 23 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl/Pf | 23 | suppressed |
| Ramipril | Ramipril | 23 | suppressed |
| Testosterone | Testosterone | 23 | suppressed |
| Azithromycin | Azithromycin | 22 | 19 |
| Digoxin | Digoxin | 22 | suppressed |
| Ezetimibe | Ezetimibe | 22 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 22 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 21 | suppressed |
| Finasteride | Finasteride | 21 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 21 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 21 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 20 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 20 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 19 | suppressed |
| Lovastatin | Lovastatin | 19 | suppressed |
| Myrbetriq | Mirabegron | 19 | suppressed |
| Nifedipine Er | Nifedipine | 19 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 18 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 18 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 17 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 17 | suppressed |
| Clonazepam | Clonazepam | 17 | suppressed |
| Irbesartan | Irbesartan | 17 | suppressed |
| Sucralfate | Sucralfate | 17 | suppressed |
| Carisoprodol | Carisoprodol | 16 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 16 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 16 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 16 | suppressed |
| Valsartan | Valsartan | 16 | suppressed |
| Aripiprazole | Aripiprazole | 15 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 15 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 15 | suppressed |
| Estradiol | Estradiol | 15 | suppressed |
| Glipizide Er | Glipizide | 15 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 15 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 15 | suppressed |
| Telmisartan | Telmisartan | 15 | suppressed |
| Carbamazepine Er | Carbamazepine | 14 | suppressed |
| Cephalexin | Cephalexin | 14 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 14 | suppressed |
| Diazepam | Diazepam | 14 | suppressed |
| Lorazepam | Lorazepam | 14 | 11 |
| Metronidazole | Metronidazole | 14 | suppressed |
| Naproxen | Naproxen | 14 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 14 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Colchicine | Colchicine | 13 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 13 | suppressed |
| Glipizide | Glipizide | 13 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 13 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 13 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 13 | suppressed |
| Lamotrigine | Lamotrigine | 13 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 13 | suppressed |
| Lubiprostone | Lubiprostone | 13 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 13 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 13 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 12 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Dulera | Mometasone/Formoterol | 11 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 11 | suppressed |
| Linzess | Linaclotide | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | suppressed |
| Pregabalin | Pregabalin | 11 | suppressed |
| Wegovy | Semaglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $464.40 · 16 records | Amgen Inc. | AREXVY, COREVALVE EVOLUT R, EVENITY, FREESTYLE LIBRE 3, LEQVIO, LOREEV XR, MINIMED 780G, MOUNJARO, OTEZLA, Ozempic, PROLIA, RECORLEV, REPATHA, Rybelsus, SHINGRIX, TERIPARATIDE, ZEPBOUND | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error